188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands

Rose, Michael R.

doi:10.1016/j.nmd.2013.08.007

Cited by 320 publications

(298 citation statements)

References 65 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…For this study, with a focus on association with systemic inflammatory diseases and malignancy, patients lacking muscle weakness and incidence, the Bohan and Peter classification offered obvious advantages. We further acknowledge the value of the recently proposed classification of IBM (Rose, 2013). But, requiring more specific muscle status data that were not available for this study, its application would not have affected the sensitivity or specificity for the IBM group, as a whole, compared to the used Griggs classification.…”

Section: Discussionmentioning

confidence: 96%

“…In our cohort five patients without any raised suspicion of malignancy were followed for less than 4 years, and an undiagnosed neoplastic disease cannot be excluded in these cases. Due to the well‐known risk of misclassifying IBM patients as polymyositis (Rose, 2013), and the relative paucity of inflammation in the more recent, pathologically defined, group, immune‐mediated necrotizing myopathy (Hoogendijk et al., 2004) (in this study classified as polymyositis), a particular effort was made to correctly identify and classify these patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

et al. 2017

View full text Add to dashboard Cite

ObjectivesIdiopathic inflammatory myopathies (IIM) are often associated with other immune‐mediated diseases or malignancy. Some studies have reported a high frequency of celiac disease in IIM. The aim of this study was to investigate the prevalence of celiac disease, systemic inflammatory diseases, and malignancy in a cohort of IIM patients, and estimate the incidence of IIM in the county of Östergötland, Sweden.Material and MethodsWe reviewed medical records and analyzed sera from 106 patients, fulfilling pathological criteria of inflammatory myopathy, for the presence of IgA antibodies against endomysium and gliadin. Antibody‐positive patients were offered further investigation with small bowel biopsy or investigation for the presence of antibodies against antitissue transglutaminase (t‐TG). The patients were classified according to Bohan and Peter or Griggs criteria. The presence of celiac disease, systemic inflammatory, and malignant diseases was documented.ResultsFour of 88 patients classified as IIM (4.5%) had biopsy‐confirmed celiac disease, which is higher than the prevalence in the general population, detected with a similar screening procedure (0.53%). Thirty‐three patients (38%) had a systemic inflammatory disease and five (5.7%) a malignancy. The incidence of confirmed IIM in the county of Östergötland was 7.3 per million/year.ConclusionsThe results highlight the high frequency of associated inflammatory and malignant diseases and confirm an increased prevalence of celiac disease in IIM.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…We selected IBM patients who satisfied Sakai 7 the European Neuromuscular Centre (ENMC) IBM Research Diagnostic Criteria 2011 [6], and applied the classification as follows: clinicopathologically defined IBM, clinically defined IBM, and probable IBM.…”

Section: Patientsmentioning

confidence: 99%

“…With reference to the pathological features of IBM (endomysial inflammatory infiltrates; rimmed vacuoles; protein accumulation; and upregulation of HLA class I around muscle fibers), we made a clinicopathological diagnosis of IBM [6]. Patients who demonstrated only these features were designated as typical IBM without granuloma group.…”

Section: Case Classificationmentioning

confidence: 99%

Inclusion body myositis with granuloma formation in muscle tissue

Sakai

Ikeda

Ishida

et al. 2015

Neuromuscular Disorders

View full text Add to dashboard Cite

show abstract

“…The increasing research efforts over the past 45 years, together with accumulated clinical experience, allows physicians today to reliably diagnose the disease not exclusively due to histopathological changes in muscle biopsies but rather through an integrated approach, using clinical and histological observations alike. Therefore, more recently defined diagnostic criteria do not call for the presence of all typical pathological hallmarks but employ the presence of defined patterns of clinical, laboratory, and histological features to categorize the diagnosis into either clinicopathologically defined IBM , clinically defined IBM or probable IBM 12, 42. One study applying machine learning algorithms to construct data‐derived IBM diagnostic criteria claims that the combinational approach of finger flexor or quadriceps weakness, endomysial inflammation, and either invasion of nonnecrotic muscle fibers or rimmed vacuoles, performed with a 90% sensitivity and 96% specificity among 371 patients 43…”

Section: Diagnosismentioning

confidence: 99%

Immune and myodegenerative pathomechanisms in inclusion body myositis

Keller

Schmidt

Lünemann

2017

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Inclusion Body Myositis (IBM) is a relatively common acquired inflammatory myopathy in patients above 50 years of age. Pathological hallmarks of IBM are intramyofiber protein inclusions and endomysial inflammation, indicating that both myodegenerative and inflammatory mechanisms contribute to its pathogenesis. Impaired protein degradation by the autophagic machinery, which regulates innate and adaptive immune responses, in skeletal muscle fibers has recently been identified as a potential key pathomechanism in IBM. Immunotherapies, which are successfully used for treating other inflammatory myopathies lack efficacy in IBM and so far no effective treatment is available. Thus, a better understanding of the mechanistic pathways underlying progressive muscle weakness and atrophy in IBM is crucial in identifying novel promising targets for therapeutic intervention. Here, we discuss recent insights into the pathomechanistic network of mutually dependent inflammatory and degenerative events during IBM.

show abstract

188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands

Cited by 320 publications

References 65 publications

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

Increased prevalence of celiac disease in idiopathic inflammatory myopathies

Inclusion body myositis with granuloma formation in muscle tissue

Immune and myodegenerative pathomechanisms in inclusion body myositis

Contact Info

Product

Resources

About